Panel Discussion | From Slowing Progression to Halting Entirely: Debating the “What’s Next” for Diabetic, Hypertensive & Rare Kidney Diseases

Time: 3:30 pm
day: Conference Day 2


  • From SGLT2s and ERAs, to GLP1s and anti-APRIL: where is the field heading next?
  • Evaluating the most exciting opportunities for new treatment options
  • Shifting the focus towards more pivotal therapies specific to underlying kidney pathophysiology, with an end goal of stopping, rather than slowing, CKD progression